Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse.

@article{Westwood2013RituximabFT,
  title={Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse.},
  author={J-P Westwood and Hailey Webster and Siobhan McGuckin and Vickie Mcdonald and Samuel J. Machin and M. Scully},
  journal={Journal of thrombosis and haemostasis : JTH},
  year={2013},
  volume={11 3},
  pages={481-90}
}
BACKGROUND Rituximab has been documented in the treatment of acute (≤ 3 days from admission), relapsed/refractory thrombotic thrombocytopenic purpura (TTP) and given as prophylaxis in selected cases to prevent acute relapse. The precise timing of rituximab in acute TTP has not been determined. OBJECTIVE To perform a retrospective analysis of rituximab use in a large TTP referral center over an 8-year period. PATIENTS/METHODS We assessed response to treatment and outcome for all patients… CONTINUE READING